How Intralymphatic Immunotherapy Can Affect Quality of Life and Symptoms in Patients With Permanent Seasonal Allergic Rhinitis, a Quasi-Experimental Design

Abstract BackgroundAllergen-specific immunotherapy is known as the only disease-modifying treatment for IgE-mediated allergic disorders. Intra lymphatic immunotherapy (ILIT) is a safe, effective, and time-saving alternative to subcutaneous immunotherapy (SCIT). This study aimed to evaluate the effects and safety of ILIT in patients with moderate to severe allergic rhinitis. MethodsIn this clinical trial, fifteen patients with moderate to severe allergic rhinitis between 18-65 years old received monthly intralymphatic inguinal injections of an active allergen (1000 SQ-U Salsola kali pollen). Clinical effects were assessed before and 4 weeks after treatment and at two consecutive pollination seasons and following non-pollination season in April.ResultsNo moderate or severe reactions were recorded following the ILIT treatment. Lymph node enlargement, local itching/erythema were seen in 6.7%, 13.3% of total respectively one day after injection. Patients who received ILIT experienced a significant clinical improvement in self-recorded seasonal allergic symptoms after treatment, as compared to themselves before ILIT. Quality of life significantly got better based on the Mini RQLQ questionnaire.ConclusionAlthough this study is based on a limited number of patients, ILIT with Salsola-pollen extract appears to decrease symptoms of allergic rhinitis without causing any crucial complications.This clinical trial study was recorded in the Iran Registry of Clinical Trials (IRCT20161206031256N2).

Download Full-text

Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastineversusloratadine

Clinical Otolaryngology ◽

10.1111/coa.12695 ◽

2016 ◽

Vol 42 (2) ◽

pp. 218-224 ◽

Cited By ~ 3

Author(s):

R.B. Locks ◽

K. dos Santos ◽

J. da Silva

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Allergic Rhinitis

Download Full-text

Subcutaneous Immunotherapy Improves the Symptomatology of Allergic Rhinitis

International Archives of Otorhinolaryngology ◽

10.1055/s-0035-1564437 ◽

2015 ◽

Vol 20 (01) ◽

pp. 006-012 ◽

Cited By ~ 3

Author(s):

Edmir Lourenço ◽

Eduardo Caldeira ◽

César Carvalho ◽

Marcelo Cunha ◽

Marcus Carvalho ◽

...

Keyword(s):

Quality Of Life ◽

Allergic Rhinitis ◽

Nasal Congestion ◽

Average Score ◽

Subcutaneous Immunotherapy ◽

Therapeutic Tool ◽

Pathological Conditions ◽

In The Beginning ◽

Subcutaneous Specific Immunotherapy

Introduction The relevance of allergic rhinitis is unquestionable. This condition affects people's quality of life and its incidence has increased over the last years. Objective Thus, this study aims to analyze the effectiveness of subcutaneous injectable immunotherapy in cases of nasal itching, sneeze, rhinorrhea and nasal congestion in allergic rhinitis patients. Methods In the present study, the same researcher analyzed the records of 281 patients. Furthermore, the researchers identified allergens through puncture cutaneous tests using standardized extracts containing acari, fungi, pet hair, flower pollen, and feathers. Then, the patients underwent treatment with subcutaneous specific immunotherapy, using four vaccine vials for desensitization, associated with environmental hygiene. The authors analyzed conditions of nasal itching, sneeze, rhinorrhea, and nasal congestion throughout the treatment, and assigned them with a score ranging from zero (0), meaning absence of these symptoms to three (3), for severe cases. The symptoms were statistically compared in the beginning, during, and after treatment. Results In this study, authors analyzed the cases distribution according to age and the evolution of symptomatology according to the scores, comparing all phases of treatment. The average score for the entire population studied was 2.08 before treatment and 0.44 at the end. These results represent an overall improvement of ∼79% in symptomatology of allergic rhinitis in the studied population. Conclusion The subcutaneous immunotherapy as treatment of allergic rhinitis led to a reduction in all symptoms studied, improving the quality of life of patients, proving itself as an important therapeutic tool for these pathological conditions.

Download Full-text

Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: A controlled clinical trial

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2003.12.589 ◽

2004 ◽

Vol 113 (4) ◽

pp. 663-668 ◽

Cited By ~ 112

Author(s):

Boris A Stuck ◽

Julia Czajkowski ◽

Anna-Eva Hagner ◽

Ludger Klimek ◽

Thomas Verse ◽

...

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Allergic Rhinitis ◽

Daytime Sleepiness ◽

Seasonal Allergic Rhinitis ◽

Controlled Clinical Trial ◽

Sleep Patterns

Download Full-text

Efficacy and safety of two Ayurvedic dosage forms for Allergic rhinitis: Study protocol for an open-label randomized controlled trial

10.21203/rs.2.13359/v1 ◽

2019 ◽

Author(s):

JM Dahanayake ◽

Pathirage Kamal Perera ◽

P Galappaththy ◽

D Samaranayake

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Allergic Rhinitis ◽

Dosage Forms ◽

Open Label ◽

Randomized Controlled ◽

Nasal Symptoms ◽

Freeze Dried

Abstract Background Allergic rhinitis (AR) is an immune response of the nasal mucosa to airborne allergens and involves nasal congestion, watery nasal discharge, itching of the nose and sneezing. The symptoms of allergic rhinitis may significantly affect a patient’s quality of life and can be associated with conditions such as fatigue, headache, cognitive impairment and sleep disturbances. Various complementary and alternative medicine treatments have been used for this condition in clinical practice. The Ayurveda system of medicine is the most common complementary medicine system in Sri Lanka. The aim of this study is to find out whether the use of two preparations (decoction and its freeze dried powder) over a period of 4 weeks is able to cure the symptoms of allergic rhinitis. Study design This is a three arm open label non-inferiority randomized controlled clinical trial in patients with AR. The study duration is 28 days oral administration of the two Ayurvedic dosage forms (Decoction and freeze dried) and the antihistamine loratidine into the 3 arms allocated randomly. After a 1 week run-in period, eligible subjects are randomly assigned to the TMD12 decoction group, TMD12 freeze dried group and the antihistamine group. Total Nasal symptom Score (TNSS) of the patients are used as the primary efficacy outcome. TNSS is recorded and compared in all 3 arms prior to visit 1, at the end of 28 days, end of the first month of follow up and second month of follow up. Symptom scores of daytime nasal symptoms, night time nasal symptoms, non-nasal symptoms and Health Related Quality of Life questionnaire are used as secondary end points. Discussion This clinical trial will be able to provide supportive evidence based scientific data on classical Ayurvedic dosage forms and the new dosage forms developed as freeze dried powder in the treatment of allergic rhinitis. Also by this trial, it is expected to develop capacity to scientifically evaluate Ayurvedic treatments that may help patients having conditions such as allergic rhinitis.

Download Full-text

Efficacy and safety of two Ayurvedic dosage forms for allergic rhinitis: Study protocol for an open-label randomized controlled trial

Trials ◽

10.1186/s13063-019-4004-1 ◽

2020 ◽

Vol 21 (1) ◽

Author(s):

Jeevani Maheshika Dahanayake ◽

Pathirage Kamal Perera ◽

Priyadarshani Galappaththy ◽

Dulani Samaranayake

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Allergic Rhinitis ◽

Dosage Forms ◽

Efficacy And Safety ◽

Open Label ◽

Randomized Controlled ◽

Nasal Symptoms ◽

Freeze Dried

Abstract Background Allergic rhinitis (AR) is an immune response of the nasal mucosa to airborne allergens and involves nasal congestion, watery nasal discharge, itching of the nose, and sneezing. The symptoms of allergic rhinitis may significantly affect a patient’s quality of life and can be associated with conditions such as fatigue, headache, cognitive impairment, and sleep disturbances. Various complementary and alternative medicine treatments have been used for this condition in clinical practice. The Ayurveda system of medicine is the most common complementary medicine system practiced in Sri Lanka. The aim of this study is to examine the efficacy and safety of a decoction used in traditional Ayurveda for allergic rhinitis and its ready- to-use freeze dried formulation in comparison to an antihistamine over a period of 4 weeks on relief of symptoms in allergic rhinitis. Study design This is a three-arm, open-label, non-inferiority, randomized controlled clinical trial enrolling patients with AR. Tamalakyadi decoction containing 12 ingredients (TMD12), used in traditional Ayurveda and its freeze-dried formulation are the test products. The efficacy and safety of the two Ayurvedic dosage forms will be tested against the antihistamine loratadine. Patients with symptoms of AR will be allocated randomly into the three arms after a 1-week run-in period and the medications will be given orally for 28 days. Total Nasal symptom Score (TNSS) of the patients will be used as the primary efficacy endpoint. TNSS will be recorded and compared between the three arms prior to visit 1, at the end of 28 days, and end of the first and second months of follow-up. Symptom scores of daytime nasal symptoms, night time nasal symptoms, non-nasal symptoms and health-related quality of life questionnaire are used as secondary end points. Discussion This clinical trial will be able to provide evidence-based scientific data on Ayurvedic dosage form, TMD12, and the freeze-dried formulation in the treatment of allergic rhinitis. This trial is expected to develop capacity to scientifically evaluate various Ayurvedic treatments that are claimed to have efficacy in treatment of various disease conditions. Trial registration ISRCTN18149439 (6 May 2019).

Download Full-text

Intralymphatic Immunotherapy: A 3-year Randomized, Double-blind Study in 72 Patients With Allergic Rhinitis Due to Birch and Grass

10.21203/rs.3.rs-96348/v1 ◽

2020 ◽

Author(s):

Lars Ahlbeck ◽

Emelie Ahlberg ◽

Janne Björkander ◽

Caroline Aldén ◽

Georgia Papapavlou ◽

...

Keyword(s):

Quality Of Life ◽

Allergic Rhinitis ◽

Grass Pollen ◽

Birch Pollen ◽

Double Blind Study ◽

Life Questionnaire ◽

Chemokine Production ◽

Intralymphatic Immunotherapy ◽

Pollen Seasons

Abstract Background: There is need for a fast, efficient, and safe way to induce tolerance in patients with severe allergic rhinitis.Methods: Patients with severe birch and timothy allergy were randomized and received three doses of 0.1 ml of birch and 5-grass allergen extracts (10,000 SQ units/ml, ALK-Abelló), or birch and placebo or 5-grass and placebo by ultrasound-guided injections into inguinal lymph nodes at monthly intervals. We have no clean placebo group but the pollen seasons are mostly divided by time. Rhinoconjunctivitis Total Symptom Score, Medication Score and Rhinoconjunctivitis Quality of Life Questionnaire were evaluated before treatment and after each birch and grass pollen season during three subsequent years. Circulating proportions of T helper subsets and allergen-induced cytokine and chemokine production were analyzed by flow cytometry and Luminex.Results: The three groups reported fewer symptoms, lower use of medication and improved quality of life during the birch and grass pollen seasons each year after treatment at an almost similar rate independently of treatment. Mild local pain was the most common adverse event. IgE levels to birch decreased, whereas birch-induced IL-10 secretion increased in all three groups. IgG4 levels to birch and timothy and skin prick test reactivity remained mainly unchanged. Conjunctival challenge tests with timothy extract showed a higher threshold for allergen. In all three groups, regulatory T cell frequencies were increased three years after treatment.Conclusion: Intralymphatic immunotherapy against grass and birch pollen allergy was safe, seemed to be effective, and to be associated with bystander immune modulatory responses.Trial registration: EudraCT (2013-004726-28). Registered 14 January 2014https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004726-28

Download Full-text

Comparing the effects of ketotifen fumarate eye drops and ketotifen oral pills on symptom severity and quality of life in patients with allergic rhinitis: a double-blind randomized clinical trial

International Forum of Allergy & Rhinology ◽

10.1002/alr.21491 ◽

2015 ◽

Vol 5 (5) ◽

pp. 386-391 ◽

Cited By ~ 4

Author(s):

Asghar Akhavan ◽

Hamidreza Karimi-Sari ◽

Mohammad Hossein Khosravi ◽

Esmaeil Arefzadeh ◽

Mohammadhosein Yavarahmadi

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Allergic Rhinitis ◽

Randomized Clinical Trial ◽

Symptom Severity ◽

Eye Drops ◽

Double Blind ◽

Ketotifen Fumarate

Download Full-text

Treatment of Seasonal Allergic Rhinitis Using Homeopathic Preparation of Common Allergens in the Southwest Region of the US: A Randomized, Controlled Clinical Trial

Annals of Pharmacotherapy ◽

10.1345/aph.1e387 ◽

2005 ◽

Vol 39 (4) ◽

pp. 617-624 ◽

Cited By ~ 25

Author(s):

Linda S Kim ◽

June E Riedlinger ◽

Carol M Baldwin ◽

Lisa Hilli ◽

Sarv Varta Khalsa ◽

...

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Allergic Rhinitis ◽

Seasonal Allergic Rhinitis ◽

Short Form ◽

Life Questionnaire ◽

Sf 36 ◽

The Us ◽

Southwest Region

BACKGROUND: Studies using homeopathy have reported beneficial effects from treating allergy-related conditions. OBJECTIVE: To investigate the effects of a homeopathic drug prepared from common allergens (tree, grass, weed species) specific to the Southwest region of the US. METHODS: A 4-week, double-blind clinical trial comparing homeopathic preparations with placebo was conducted in the Phoenix metropolitan area during the regional allergy season from February to May. Participants included 40 men and women, 26–63 years of age, diagnosed with moderate to severe seasonal allergic rhinitis symptoms. Study outcomes included allergy-specific symptoms using the rhinoconjunctivitis quality-of-life questionnaire (RQLQ), functional quality of life using the Medical Outcomes Study Short Form-36 (MOS SF-36), and the work productivity and activity impairment (WPAI) questionnaire. RESULTS: Scales from the RQLQ, MOS SF-36, and WPAI questionnaire showed significant positive changes from baseline to 4 weeks in the homeopathic group compared with the placebo group (p < 0.05). Subjects reported no adverse effects during the intervention period. CONCLUSIONS: These preliminary findings indicate potential benefits of the homeopathic intervention in reducing symptoms and improving quality of life in patients with seasonal allergic rhinitis in the Southwestern US.

Download Full-text

Long-term efficacy of standardised specific subcutaneous immunotherapy in children with persistent allergic rhinitis due to multiple allergens including house dust mites

The Journal of Laryngology & Otology ◽

10.1017/s0022215117002547 ◽

2018 ◽

Vol 132 (3) ◽

pp. 230-235 ◽

Cited By ~ 4

Author(s):

Y Song ◽

J Long ◽

T Wang ◽

J Xie ◽

M Wang ◽

...

Keyword(s):

Quality Of Life ◽

Allergic Rhinitis ◽

House Dust ◽

House Dust Mites ◽

Subcutaneous Immunotherapy ◽

Life Questionnaire ◽

Dust Mites ◽

Persistent Allergic Rhinitis

AbstractObjectives:To observe the five-year efficacy of standardised specific subcutaneous immunotherapy for house dust mite allergy in monosensitised and polysensitised children with persistent allergic rhinitis.Methods:From January 2007 to August 2009, 236 children with persistent allergic rhinitis were divided into 2 groups: 1 group received standardised specific subcutaneous immunotherapy using house dust mite extract; the other received pharmacotherapy with intranasal corticosteroids and oral antihistamines. A total of 193 patients (106 in the immunotherapy group and 87 in the pharmacotherapy group) completed treatment. Scores for symptoms, total medication and quality of life were evaluated.Results:The subcutaneous immunotherapy group demonstrated a significant reduction in visual analogue scale scores, Rhinoconjunctivitis Quality of Life Questionnaire scores and total medication scores (p < 0.05) compared with the pharmacotherapy group. No significant differences in the visual analogue scale and Rhinoconjunctivitis Quality of Life Questionnaire scores were found between the polysensitised and monosensitised subgroups (p > 0.05). No serious adverse events occurred.Conclusion:Standardised subcutaneous immunotherapy has long-term efficacy for children with persistent allergic rhinitis. Single-allergen subcutaneous immunotherapy was appropriate for allergic rhinitis caused by multiple allergens, including house dust mites, in the paediatric population.

Download Full-text